AIDX 20/20 Biolabs, Inc.
Company Analysis
Latest News
AIDX Provides Business Update Highlighting FDA Engagement and Q2 Commercial Progress
AIDX (20/20 Biolabs, Inc.) provided a business update via an investor presentation, detailing recent preliminary discussions with the FDA for its OneTest...
🟢 20/20 Biolabs is trading 5.56% up today as XBI gains 2.75%
20/20 Biolabs is trading at $0.65 with a +5.56% gain, primarily amid biotech-sector strength. - Biotech stocks provided a supportive backdrop, with XBI up...
🟢 20/20 Biolabs is trading 7.11% up in pre-market; no confirmed catalyst identified
20/20 Biolabs is trading at $0.66, 7.11% up after closing at $0.62 on August 31, 2026, with no confirmed company-specific catalyst identified for the...
🟢 20/20 Biolabs is trading 7.11% up in after-hours trading with no confirmed catalyst
20/20 Biolabs is trading at $0.66, +7.11% in after-hours trading, with no confirmed August 31 company-specific announcement or late-breaking filing explaining...
🟢 20/20 Biolabs is trading 5.27% up in after-hours trading
20/20 Biolabs is trading 5.27% up at $0.66 in after-hours trading after closing at $0.62 on August 28, 2026, with no clear catalyst identified. - The...
🟢 20/20 Biolabs is trading 8.69% up today
20/20 Biolabs is trading at $0.66 (+8.69%), extending its recent advance after closing at $0.62 on August 27 and $0.56 on August 26. - No company announcement...
🟢 20/20 Biolabs is trading 11.87% up today as Nvidia outlook lifts AI-related stocks
20/20 Biolabs is trading 11.87% up now at $0.63, with the move appearing primarily driven by positive global market sentiment after Nvidia’s strong outlook...
🟢 20/20 Biolabs is trading 6.55% up today as Nasdaq Composite rises 1.00%
20/20 Biolabs is trading at $0.60, up 6.55%, amid stronger risk appetite as the Nasdaq Composite rises 1.00% during the session. - No clearly disclosed...
🟢 20/20 Biolabs is trading 8.8% up today amid biotech sector strength, catalyst uncertain
20/20 Biolabs is trading 8.8% up now at $0.57, with biotech sector strength providing a supportive backdrop. - XBI is up 2.06%. - No clearly disclosed...
🔴 20/20 Biolabs is trading 5% down in pre-market — catalyst remains unclear
20/20 Biolabs is trading 5.13% down at $0.50 after closing at $0.53 on August 25, 2026; the catalyst remains unclear. - No major company-specific announcement...
🟢 20/20 Biolabs is trading 12.42% up today as XBI gains 2.06%
20/20 Biolabs is trading at $0.58, up +12.42%, mainly amid biotechnology-sector strength, with XBI up 2.06% and the Nasdaq Composite up 0.84%. - No new...
🔴 20/20 Biolabs is trading 5% down today amid a 0.65% Nasdaq Composite decline
20/20 Biolabs is trading at $0.53, down 5.20%, on August 24, 2026, as broader risk-off pressure may be contributing amid a weaker Nasdaq Composite. - No new...
🟢 20/20 Biolabs is trading 7.90% up today after strong Q2 revenue and margin growth
- Q2 revenue increased 36.5% to $0.7 million, with OneTest revenue rising 47.1%. - Gross profit climbed 86.6%, and gross margin expanded to 41.7%. - The...
🟢 20/20 Biolabs is trading 6.94% up today after Q2 revenue rose 36.5%
20/20 Biolabs is trading at $0.55, up 6.94% on August 21, 2026, following Q2 revenue growth and gross-margin expansion. - Q2 revenue rose 36.5% to $0.7...
🟢 20/20 Biolabs is trading 5.9% up in pre-market after Q2 revenue rose 36.5%
20/20 Biolabs is trading at $0.54, +5.9% in pre-market after Q2 revenue rose 36.5% year over year. - Revenue reached $0.7 million, while gross margin expanded...
20/20 Biolabs Posts Record Cancer-Test Quarter, but Can $0.7 Million in Revenue Sustain a Company Burning Through Millions?
Shares of 20/20 Biolabs (AIDX) rose 7.7% to $0.56 as investors digested what the company called its strongest-ever quarter for its AI-powered cancer blood...
🟢 20/20 Biolabs is trading 7.73% up today after revenue growth and expanded gross margins
20/20 Biolabs is trading 7.73% up now at $0.56 after investors continued assessing its August 17 earnings report. - Second-quarter revenue rose 36.5% year...
🔴 20/20 Biolabs is trading 7.12% down today as risk-off sentiment pressures growth stocks
20/20 Biolabs is trading 7.12% down at $0.51 as broader risk-off sentiment pressures growth-oriented stocks, with major U.S. indexes also lower on August 18,...
🔴 20/20 Biolabs is trading 5.42% down today in pre-market after Q2 net loss widened
20/20 Biolabs is trading 5.42% down at $0.52 after its August 17, 2026, second-quarter report showed revenue growth but a wider net loss. - Revenue rose 36.5%...
20/20 Biolabs, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 19, 2026
Analysts expect 20/20 Biolabs (AIDX) to report Q2 2026 revenue of approximately $0.89 million and a consensus EPS loss of $0.06, with the current share price...